Bayer (OTCMKTS:BAYRY) Downgraded by ValuEngine

Bayer (OTCMKTS:BAYRY) was downgraded by stock analysts at ValuEngine from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Wednesday, ValuEngine reports.

A number of other analysts have also recently commented on BAYRY. Zacks Investment Research cut shares of Bayer from a “hold” rating to a “sell” rating and set a $17.00 target price on the stock. in a report on Wednesday, August 7th. Bank of America upgraded shares of Bayer from a “neutral” rating to a “buy” rating in a research note on Friday, August 16th. Three research analysts have rated the stock with a sell rating, three have issued a hold rating and two have issued a buy rating to the stock. Bayer currently has an average rating of “Hold” and an average price target of $17.00.

BAYRY traded down $0.14 during trading on Wednesday, reaching $19.04. The stock had a trading volume of 278,947 shares, compared to its average volume of 735,501. The stock’s 50 day moving average is $17.79 and its two-hundred day moving average is $17.11. The company has a current ratio of 1.37, a quick ratio of 0.92 and a debt-to-equity ratio of 0.79. The company has a market capitalization of $71.02 billion, a price-to-earnings ratio of 10.88, a P/E/G ratio of 1.01 and a beta of 1.03. Bayer has a one year low of $14.61 and a one year high of $23.50.

Bayer Company Profile

Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, Crop Science, and Animal Health segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.

Recommended Story: Mutual Funds

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Bayer (OTCMKTS:BAYRY)

Receive News & Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related companies with's FREE daily email newsletter.